Tesamorelin vs CJC-1295: GH Secretagogue Research Comparison

Growth Hormone Secretagogue Class

Growth hormone-releasing hormone (GHRH) is a 44-amino-acid hypothalamic peptide that stimulates the anterior pituitary to release growth hormone (GH). Both Tesamorelin and CJC-1295 are synthetic GHRH analogues, but they differ in molecular modifications, pharmacokinetics, and pulsatility profile. Researchers studying the GH axis often compare them when designing in-vitro and animal protocols examining endogenous GH release patterns versus sustained elevation.

Tesamorelin: Stabilised Full-Length GHRH Analogue

Tesamorelin is a 44-amino-acid GHRH analogue with a trans-3-hexenoic acid moiety attached to the N-terminus. This modification protects the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), which would otherwise cleave native GHRH within minutes of administration. The result is a peptide with the full native GHRH sequence and signalling profile, but with substantially extended in-vivo stability. Tesamorelin preserves the natural pulsatile pattern of GH secretion, meaning research models show GH peaks and troughs consistent with physiological release rhythms.

CJC-1295: Modified GHRH(1-29) with Optional DAC

CJC-1295 is a 30-amino-acid truncated GHRH(1-29) analogue with four amino acid substitutions that improve resistance to enzymatic degradation and increase receptor binding affinity. The compound exists in two research forms: CJC-1295 without DAC (also called Mod GRF 1-29) and CJC-1295 with DAC (Drug Affinity Complex), the latter adding a maleimidopropionic acid linker that binds to circulating albumin. Without DAC, CJC-1295 has a half-life of around 30 minutes and preserves pulsatile GH release. With DAC, the half-life extends to approximately 8 days, producing sustained rather than pulsatile GH elevation.

Pulsatile vs Sustained Release Profiles

The distinction between pulsatile and sustained GH elevation is mechanistically important. Native GH secretion in mammals follows a pulsatile pattern with peaks every 3-5 hours and troughs near zero. Pulsatile signalling activates STAT5b-dependent gene expression in target tissues such as the liver, driving IGF-1 production in characteristic patterns. Sustained GH elevation, as produced by CJC-1295 with DAC, generates a flatter signalling curve that activates different downstream transcriptional pathways. Tesamorelin and non-DAC CJC-1295 preserve pulsatility. DAC-modified CJC-1295 abolishes it. Research model selection between the two often depends on whether physiological pulsatility is required.

Research Applications

Tesamorelin has been extensively studied in HIV-associated lipodystrophy research, where visceral adipose tissue reduction was demonstrated in clinical trials published by Falutz and colleagues in the New England Journal of Medicine in 2007. CJC-1295 with and without DAC has been used in research examining GH/IGF-1 axis kinetics, body composition models, and combination protocols with GH-releasing peptide analogues such as Ipamorelin. The combination of a GHRH analogue with a ghrelin-mimetic GHRP is a frequently studied protocol in pituitary signalling research.

Laboratory Handling

Both peptides are supplied as lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by injecting slowly down the side of the vial and gently swirling. Store reconstituted solutions at 2-8°C and use within 4 weeks. Tesamorelin and CJC-1295 are both sensitive to repeated freeze-thaw cycles which compromise peptide integrity.

Sourcing in the UK

Peptaro supplies research-grade Tesamorelin 5mg, CJC-1295 5mg, and CJC-1295 with DAC 5mg with the certificate of analysis for each batch published on the product page. Same-day UK dispatch on orders before 3pm UK time, free tracked UK delivery on every order. For in-vitro laboratory research use only. Vial sizes and pricing are listed on the Tesamorelin UK and CJC-1295 UK buy pages.